drugset / Trial / NCT05172518
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
Phase 3
Not yet recruiting
512 enrolled
Sun Yat-sen University
Chengdu Biostar Pharmaceuticals · collab
RandomizedFactorialOpen-labelTreatment
Summary
It is a phase III trial to explore the efficacy and safety of utidelone plus capecitabine versus taxane plus capecitabine in HER2-negative locally advanced or metastatic breast cancer and the differences of metronomic capecitabine and intermittent capecitabine in combination chemotherapy.
Timeline
- Start
- 2022-03-01
- Primary completion
- 2027-03-01
- Completion
- 2030-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 500 mg | — |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Comparator | Docetaxel | Small molecule | — | — |
| Subject | Epothilone D | Small molecule | 30 mg/m2 | — |
| Comparator | Nab-paclitaxel | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |